Anticytokine therapy - New approach to the treatment of autoimmune and cytokine-disturbance diseases

Medical Hypotheses

Volumn 59, Issue 6, 2002, Pages 770-780

  Skurkovich, S V ^a   Skurkovich, B ^a,b   Kelly, J A ^a  

^a Advanced Biotherapy   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON ANTIBODY; CYTOKINE ANTIBODY; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; HYDROCORTISONE; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; CYTOKINE; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALOPECIA AREATA; ALZHEIMER DISEASE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; COMA; DIABETES MELLITUS; EMBRYO DEVELOPMENT; GRAFT REJECTION; HUMAN; MENTAL DISEASE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE; VITILIGO; BIOLOGICAL MODEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; MODELS, IMMUNOLOGICAL; RANDOMIZED CONTROLLED TRIALS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036905461     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(02)00346-8     Document Type: Article

References (84)

1. Skurkovich S. V., Klinova E. G., Eremkina E. I., Levina N. V. Immunosuppressive effect of an anti-interferon serum. Nature 1974; 247: 551-552.
2. Skurkovich S. V., Klinova E. G., Aleksandrovskaya I. M. et al. Stimulation of transplantation immunity and plasma cell reaction by interferon in mice. Immunology 1973; 25: 317.
3. Skurkovich S, Skurkovich B. The role of interferon in the development of autoimmune diseases and allergy (immediate hypersensitivity). In: Third Annual International Congress for Interferon Research, November 1-2, 1982.
4. Singh V. K., Mehrotra S., Agarwal S. S. The paradigm of Th1 and Th2 cytokines. Immunol Res 1999; 20: 147-161.
5. Skurkovich S. V., Eremkina E. I. Probable role of interferon in allergy. Ann Allergy 1975; 35: 356-360.
6. Skurkovich SS, Steinberg A, Skurkovich B, Harrell S. Interferon in the serum of autoimmune NZB/W and MRL/lpr/lpr mice. In: Second Annual International Congress for Interferon Research, San Francisco, 21-23 October 1981.
7. Hooks J. J., Moutsopoulos H. M., Geis S. A. et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5.
8. Preble O, Black R, Harrell S, Skurkovich S, Friedman R, and Klippel J. Interferon production by patients with systemic lupus erythematosis (SLE) or rheumatoid arthritis (RA). In: Second Annual International Congress for Interferon Research, San Francisco, 21-23 October 1981.
9. Preble O. T., Black R. J., Friedman R. M., Klippel J. H., Vilcek J. Systemic lupus erythematosus: Presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982; 216: 429-431.
10. Skurkovich S., Skurkovich B., Bellanti J. A. A unifying model of the immunoregulatory role of the interferon system: Can interferon produce disease in humans?. Int J Immunol Immunopathol 1987; 43: 362-373.
11. Skurkovich S. V., Skurkovich B. Development of autoimmune disease is connected with the initial disturbance of IFN synthesis in the cells. J IFN Res 1989; 9: S2.
12. Elliott M. J., Maini R. N., Feldmann M. et al. Treatment of rheumatoid arthritis with chimaeric monoclonal antibodies to tumour necrosis factor-α. Arthritis Rheum 1993; 36: 1681-1690.
13. Stewart T. A., Hultgren B., Huang X., Pitts-Meek S., Hully J., MacLachlan N. J. Induction of type I diabetes by interferon-α in transgenic mice. Science 1993; 260: 1942-1946.
14. Jacob C. O., van der Meide Ph., McDevitt H. O. In vivo treatment of (NZB x NZW) F1 lupus-like nephritis with monoclonal antibody to γ-interferon. J Exp Med 1987; 166: 798.
15. Conlon K. C., Urba W. J., Smith II J. W. et al. Exacerbation of symptoms of AD in patients receiving α-interferon therapy. Cancer 1990; 65: 2237.
16. Ronnblom L. E., Alm G. V., Obert K. E. Possible induction of systemic lupus erythematosus by interferon-α treatment in patients with a malignant carcinoid tumor. Ann Int Med 1991; 115: 178.
17. Skurkovich S., Skurkovich B., Bellanti J. A. A disturbance of interferon synthesis with the hyperproduction of unusual kinds of interferon can trigger autoimmune disease and play a pathogenetic role in AIDS; the removal of these interferons can be therapeutic. Med Hypotheses 1994; 42: 27-35.
18. Skurkovich S. V., Loukina G. V., Sigidin Y. A., Skurkovich B. Successfull first-time use of antibodies to interferon-γ alone and combined with antibodies to tumor necrosis factor-alpha treat rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, Behcet's syndrome). Int J Immunotherapy 1998; 14: 23-32.
19. Sigidin Y. A., Loukina G. V., Skurkovich B., Skurkovich S. Randomized, double-blind trial of anti-interferon-γ antibodies in rheumatoid arthritis. Scan J Rheumatol 2001; 30: 203-207.
20. Loukina G, Sigidin Ya, Pushkova O, Skurkovich B, Skurkovich S. Immunotherapy of acute rheumatoid arthritis (double-blind, placebo-controlled study using anti-IFN-γ and anti-IFN-α antibodies). In: Federation of Clinical Immunology Society (FOCIS) 2nd Annual Meeting, San Francisco, June 28, 2002.
21. Skurkovich S., Boiko A., Beliaeva I., Buglak A., Alekseeva T., Smirnova N. et al. Randomized study of antibodies to IFN-γ and TNF-α in secondary progressive multiple sclerosis. Multiple Sclerosis 2001; 7: 277-284.
22. Skurkovich S., Sigidin Y., Loukina G., Alexandrovsky Y., Chekhonin V., Skurkovich B. Successful anti-cytokine therapy using antibodies to IFN-γ, IFN-α and TNF-α in patients with acute rheumatoid arthritis (RA), psoriatic arthritis (PA), and schizophrenia. Eur Cytokine Network 1998; 9: 451.
23. Skurkovich S. V., Kasparov A., Narbut N., Skurkovich B. Treatment of corneal transplant rejection in humans with anti-interferon antibodies. Am J Opthalmol 2002; 133(6): 829-830.
24. Skurkovich S, Korotky NG, Sharova NM, Skurkovich B. Successful anti-IFN-γ therapy of alopecia areata, vitiligo, and psoriasis. In: Federation of Clinical Immunology Society (FOCIS) 2nd Annual Meeting, June 28, 2002.
25. Foster G. R., Finter N. B. Are all type I human interferons equivalent?. J Viral Hepatitis 1998; 5: 142-152.
26. Marzi M., Vigano A., Trabattoni D., Villa M. L., Salvaggio A., Clerici E., Clerici M. Characterization of type I and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol 1996; 106: 127-133.
27. McBridge W. A. Thalidomide and congenital abnormalities. Lancet 1996; 2: 1358.
28. Lee J. Y., Bowden D. S. Rubella virus replication and links to teratogenicity. Clin Microbiol Rev 2000; 13: 571-587.
29. DeStefano E., Friedman R. M., Friedman-Kien A. E. et al. Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy. J Infec Dis 1982; 146: 451-459.
30. Sekigawa I., Kaneko H., Hishikawa T., Hashimoto H., Hirose S., Kaneko Y., Maruyama N. HIV infection and SLE: Their pathogenic relationship. Clin Exp Rheumatol 1998; 16: 175-180.
31. Talal N., Flescher E., Dang H. Are endogenous retroviruses involved in human autoimmune disease?. J Autoimmun 1992; 5(Suppl A): 61-66.
32. Herrmann M., Hagenhofer M., Kalden J. R. Retrovirus and systemic lupus erythematosus. Immunol Rev 1996; 152: 145-156.
33. Zagury D., Lachgar A., Chams V. et al. Interferon-α and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA 1998; 95: 3851-3856.
34. Vadhan Raj, Wong S. G., Gnecco C., Cunningham-Rundles S., Krim M., Real F. X., Oettgen H. F., Krown S. E. Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome. Cancer Res 1986; 46: 417-425.
35. Kim T., Kanayama Y., Negoro N., Okamura M., Takeda T., Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987; 70: 562-569.
36. Clerici M., Galli M., Bosis S., Gervasoni C., Moroni M., Norbiato G. Immunoendocrinologic abnormalities in human immunodeficiency virus infection. Ann NY Acad Sci 2000; 917: 956-961.
37. Lau A. S., Williams B. R. G. The role of interferon and tumor necrosis factor in the pathogenesis of AIDS. J Exp Pathology 1990; 5: 111-122.
38. Gringeri A., Santagostino E., Cucini M. et al. Absence of clinical, biological, and immunological signs of progression in HIV-1 infected patients receiving active anti-IFNα immunization. Thirty months follow-up report. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: 55-67.
39. Revel M., Chebath J., Mangelus M. et al. Antagonism of interferon beta on interferon γ: Inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Multiple Sclerosis 1995; 1: S5-S11.
40. Moore K. W., O'Garra A., de Waal Malefyt R. et al. Interleukin 10. Annu Rev Immunol 1993; 11: 165-190.
41. Olsson T., Kelis S., Edlund C. et al. Neuronal interferon-γ immunoreactive molecule: Bioactivities and purification. Eur J Immunol 1994; 24: 308-314.
42. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFN-β Multiple Sclerosis Study Group. Neurology 1993; 43: 655-661.
43. Staeva-Vieira T. P., Freedman L. P. 1,25-Dihydroxyvitamin D(3) inhibits IFN-γ and IL-4 levels during in vitro polarization of primary murine CD4(+) T cells. J Immunol 2002; 168: 1181-1189.
44. Hayes C. E. Vitamin D: A natural inhibitor of multiple sclerosis. Proc Nutr Soc 2000; 59: 531-535.
45. Moncada S., Palmer R. M., Higgs E. A. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1994; 43: 109-142.
46. Goodwin J. L., Uemura E., Cunnick J. E. Microglial release of nitric oxide by the synergistic action of β-amyloid and IFN-γ. Brain Res 1995; 692(1-2): 207-214.
47. Gross S. S., Wolin M. S. Nitric oxide: Pathophysiological mechanisms. Annual Rev Physiol 1995; 57: 737-769.
48. Hunot S., Boissiere F., Faucheux B., Brugg B., Mouattprigent A. et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996; 72: 355-363.
49. Sanders D. B., Larson D. F., Hunter K., Gorman M., Yang B. Comparison of tumor necrosis factor-α effect on the expression of iNOS in macrophage and cardiac myocytes. Perfusion 2001; 16: 67-74.
50. Karlsson H., Bachmann S., Schroder J., McArthur J., Torrey E. F., Yolken R. H. Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc Natl Acad Sci USA 2001; 10(98): 4634-4649.
51. Christensen T., Sorensen P. D., Hansen H. J., Moller-Larsen A. Endogenous retroviruses in multiple sclerosis. Ugeskr Laeger 2001; 163: 297-301.
52. Munoz-Fernandez M. A., Fresno M. The role of tumour necrosis factor, interleukin 6, interferon-γ and inducible nitric oxide synthase in the development and pathology of the nervous system. Progr Neurobiol 1998; 56: 307-340.
53. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-126.
54. Fazio S., Linton M. F. The inflamed plaque: Cytokine production and cellular cholesterol balance in the vessel wall. Am J Cardiol 2001; 88(suppl): 12E-15E.
55. Smith D. A., Irving S. D., Sheldon J., Cole D., Kaski J. C. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 2001; 104: 746-749.
56. Blair L. A., Maggi L. B., Jr, Scarim A. L., Corbett J. A. Role of interferon regulatory factor-1 in double-stranded RNA-induced iNOS expression by mouse islets. J Biol Chem 2002; 277: 359-365.
57. Abu El-Asrar A. M., Desmet S., Meersschaert A. et al. Expression of the inducible isoform of nitric oxide synthase in the retinas of human subjects with diabetes mellitus. Am J Ophthalmol 2001; 132: 551-556.
58. Malkiel S., Kuan A. P., Diamond B. Autoimmunity in heart disease: Mechanisms and genetic susceptibility. Mol Med Today 1996; 2: 336-342.
59. Treska V., Topolcan O., Pecen L. Cytokines as plasma markers of abdominal aortic aneurysm. Clin Chem Lab Med 2000; 38: 1161-1164.
60. Skurkovich S. V., Skorikova A. S., Dubrovina N. A. et al. Lymphocytes' cytotoxicity towards cells of human lymphoblastoid lines in patients with rheumatoid arthritis and systemic lupus erythematosus. Ann Allergy 1977; 34: 344-350, Errors in Table 2.
61. Baird K. S., Crossan J. F., Ralston S. H. Abnormal growth factor and cytokine expression in Dupuytren's contracture. J Clin Pathol 1993; 46: 425-428.
62. Shiozawa S., Kuroki Y., Kim M., Hirohata S., Ogino T. Interferon-α in lupus psychosis. Arthritis Rheum 1992; 35: 417-422.
63. Stubbs G. Interferonemia and autism. J Autism Dev Disord 1995; 25: 71-73.
64. Singh V. K. Plasma increase of interleukin-12 and interferon-γ. Pathological significance in autism. J Neuroimmunol 1996; 66: 143-145.
65. Mittleman B. B., Castellanos F. X., Jacobsen L. K., Jacobsen L. K., Rapoport J. L., Swedo S. E., Shearer G. M. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 1997; 159: 2994-2999.
66. Maes M., Song C., Lin A., De Jongh R., Van Gastel A., Kenis G. et al. The effects of psychological stress on humans: Increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 1998; 10: 313-318.
67. Shuto H., Kataoka Y., Horikawa T., Fujihara N., Oishi R. Repeated interferon-α administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 1997; 747: 348-351.
68. Kaminska T., Wysocka A., Marmurowska-Michalowska H., Dubas-Slemp H., Kandefer-Szerszen M. Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch Immunol Ther Exp (Warsz) 2001; 49: 439-445.
69. Naudin J., Capo C., Giusano B., Mege J. L., Azorin J. M. A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia?. Schizophr Res 1997; 26: 227-233.
70. Stefanis C. N., Theodoropoulou-Vaidaki S., Baxevanis C. N. et al. Investigation of immune parameters in never medicated and chronically medicated schizophrenic patients. Neuropsychopharmacology 1994; 10: 35, S-80-366.
71. Skurkovich S, Alexandrovsky YA, Chekhonin VP, Ryabukhin IA, Chakhava KO, Skurkovich B. Improvement in Negative Symptoms of Schizophrenia with Antibodies to Tumor Necrosis Factor-α and to Interferon-γ (Case Study). In preparation for publication.
72. Komorowska-Pietrzykowska R., Rajewski A., Sobieska M., Wiktorowicz K. Interleukin-6, tumor necrosis factor-α and interferon-γ in patients with anorexia nervosa. Adv Exp Med Biol 2001; 495: 173-176.
73. Raymond N. C., Dysken M., Bettin K., Eckert E. D., Crow S. J., Markus K., Pomeroy C. Cytokine production in patients with anorexia nervosa, bulimia nervosa, and obesity. Int J Eat Disord 2000; 28: 293-302.
74. Maes M., Song C., Lin A. H., Bonaccorso S., Kenis G., De Jongh R. et al. Negative immunoregulatory effects of antidepressants: Inhibition of interferon-γ and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999; 20: 370-379.
75. Jarvis B., Faulds D. Etanercept: A review of its use in rheumatoid arthritis. Drugs 1999; 57: 945-966.
76. Firestein G. S., Zvaifler N. J. Anticytokine therapy in rheumatoid arthritis. N Engl J Med 1997; 337: 195-197.
77. Keane J., Gershon S., Wise R. P., Mirabile-Levens E., Kasznica J., Schwieterman W. D., Siegel J. N., Braun M. M. Tuberculosis associated with infliximab, a tumor necrosis factor α neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
78. Hamers R. Muyldermans. Immunology of camels and llamas. In: P.-P. Pastoret, P. Griebel, H. Bazin, A. Govaerts (eds). Handbook of Vertebrate Immunology. London: Academic Press, 1998: 434-435.
79. Billiau A. Interferons in multiple sclerosis: Warnings from experiences. Neurology 1995; 45(6 Suppl 6): 550-553.
80. Loukina G, Sigidin Ya, Skurkovich S, Skurkovich B. Different therapeutic responses after anti-interferon (IFN)-gamma therapy in Th1 (rheumatoid and psoriatic arthritis) and Th1/Th2 disease (systemic lupus erythematosus (SLE)). The Cytokine Odyssey 2001, November 8-11, Maui, Hawaii.
81. O'Dell J. R. Anticytokine therapy - A new era in the treatment of rheumatoid arthritis?. N Engl J Med 1999; 340: 310-312.
82. Skurkovich S. V. Immunoglobulin (hyperimmune plasma) of directed action. Soviet Medicine 1977; 7: 103-107.
83. Skurkovich S. Facing the coming plague. World & I 1998;June, 150-158.
84. Kelly J. Immunotherapy against antibiotic-resistant bacteria: The Russian experience with an antistaphylococcal hyperimmune plasma and immunoglobulin. Microbes and Infection 2000; 2: 1382-1392.